Evidence map›Paper›PMID 29528942›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2018

Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.

Agnes-Laurence Chenine, Melanie Merbah, Lindsay Wieczorek, Sebastian Molnar, Brendan Mann, Jenica Lee, Anne-Marie OʼSullivan, Meera Bose, Eric Sanders-Buell, Gustavo H Kijak and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Agnes-Laurence ChenineU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Melanie MerbahU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Lindsay WieczorekU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Sebastian MolnarU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Brendan MannU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Jenica LeeU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Anne-Marie OʼSullivanU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Meera BoseU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Eric Sanders-BuellU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Gustavo H KijakU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Carolina HerreraDepartment of Medicine, Mucosal Infection and Immunity Group, Imperial College, London, United Kingdom.
Robert McLindenU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Robert J OʼConnellU.S. Army Component the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Nelson L MichaelU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Merlin L RobbU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Jerome H KimU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Victoria R PolonisU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Sodsai TovanabutraU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.
Walter Reed Army Institute of Research · USHenry M. Jackson Foundation · USArmed Forces Research Institute of Medical Science · THBioScience Laboratories (United States) · USImperial College London · GB

Funding

Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

backgroundHIV-1 CRF01_AE is dominant in Thailand where RV144 vaccine trial was conducted. To study immune correlates of protection in ongoing trials, CRF01_AE-derived reagents are essential. Here, we present a panel of 14 HIV-1 infectious molecular clones (IMCs) identified from different stages of infection and characterization of their neutralization sensitivity using 2 standard assays.

methodsOne full-length IMC was constructed using a transmitted-founder virus to express Renilla luciferase (LucR) reporter gene and full-length envelopes (envs) of exogenous HIV-1. A panel of IMCs was generated, expressing envs of viruses from acute (Fiebig stages I/II and I-IV) and chronic (>Fiebig VI) infection. Neutralization assays were performed using TZM-bl or A3R5 cell lines, and sera or monoclonal antibodies (mAbs). Wilcoxon matched-paired test was used to assess neutralization differences between assays and reagents; correlation coefficients were evaluated by linear regression.

resultsNeutralization potency observed was significantly higher in the A3R5 assay when testing mAbs and serum pools (P < 0.0001); the stage of infection from which env was derived did not associate with IMC neutralization sensitivity. Neutralization values from A3R5 and TZM-bl assays were strongly correlated when mAbs were tested (R = 0.7, P < 0.0001), but a weaker association was seen with serum pools (R = 0.17, P = 0.03).

conclusionsThis novel panel of CRF01_AE reporter IMC is useful for assessing vaccine-induced neutralizing antibodies in multiple assays, including those using primary cell targets. The significant differences in TZM-bl and A3R5 neutralization sensitivity, as well as the poor association when using polyclonal sera indicates the need for caution in choosing one specific platform.

Indexed as

Antibodies, NeutralizingCell LineHIV-1HIV InfectionsHumansAntibodies, Neutralizing

Identifiers

PMID29528942
PMCPMC5997515
OpenAlexW2791925365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.